Merck & Co. Shares Rise on DBS Analyst's $180 Price Target

Merck & Co. shares have risen after DBS analyst Nico Chen reaffirmed his Buy stance on the stock, setting a price target of $180.00.

This represents a notable increase from previous targets and reflects confidence in Merck's pipeline and earnings trajectory.

The company's Q2 2026 revenue growth has been steady, with a 5.07% year-over-year increase to $16.6 billion, according to Quiver Quantitative.

However, pipeline risks remain, as highlighted by the publication of full phase 3 data from a failed Trodelvy lung cancer trial conducted by Merck and Gilead, which has sparked debate regarding the validity of some Chinese clinical research in Western markets.